Safety and Performance of INVICTA DF4 Ventricular Defibrillation Lead: Results From APOLLO Prospective Multicenter...

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Background:

• Implantable cardioverter-defibrillator (ICD) therapy requires reliable right ventricular leads for crucial functions.
• The INVICTA DF4 lead is a quadripolar, active-fixation design engineered for improved implant workflow, safety, and long-term performance.

Purpose of the Study:

• To evaluate the safety and performance of the INVICTA DF4 lead in de novo ICD or CRT-D implantations.
• To assess long-term electrical variables, arrhythmia termination efficacy, and lead-related complications over 24 months.

Main Methods:

• The APOLLO study was a prospective, multicenter, single-arm observational trial involving 446 adult patients across Europe.
• Patients received either a 58 or 68 cm INVICTA DF4 lead for ICD or CRT-D implantation.
• Co-primary endpoints assessed safety and performance at 3 months; secondary endpoints evaluated long-term outcomes up to 24 months.

Main Results:

• Successful implantation was achieved in 100% of 446 patients, with leads placed in the apex (57.2%) or RV septum (42.8%).
• Electrical parameters remained stable post-discharge through 24 months, demonstrating durable performance.
• The lead achieved a 97.7% success rate in terminating arrhythmic episodes and a 96.4% overall lead-related complication-free rate.

Conclusions:

• The INVICTA DF4 ventricular lead demonstrated high implant success, sustained electrical performance, and effective arrhythmia management in a large European cohort.
• Low complication rates were observed through 24 months, with a trend towards fewer complications in septal lead positioning compared to apical placement.